Spironolactone-Induced Gynecomastia: Laterality
Spironolactone-induced gynecomastia is typically bilateral, though unilateral presentation can occur and should not exclude drug-induced etiology from consideration.
Evidence from Guidelines and Drug Labels
The FDA drug label for spironolactone 1 and the 2025 Endocrine Society Clinical Practice Guideline on Primary Aldosteronism 2 both describe gynecomastia as a known adverse effect of spironolactone but do not specify whether it is typically unilateral or bilateral. The guideline notes that gynecomastia may appear as early as 1-2 months but more commonly after ≥6 months of treatment, is dose-related, and can often resolve with dose reduction to ≤50 mg daily in younger males 2.
Clinical Evidence on Laterality
The research evidence provides important clarification:
Bilateral presentation is the norm: Multiple studies and reviews discussing spironolactone-induced gynecomastia describe it as a bilateral phenomenon 3, 4, 5, 6. A 1981 case report specifically described "double-sided painful gynecomastia" in a patient on aldosterone antagonist therapy 3.
Unilateral cases do occur: A 2018 case report documented a 52-year-old male who developed painful swelling of the right breast only after 12 months of spironolactone treatment 7. The authors explicitly noted that while literature typically indicates bilateral gynecomastia with spironolactone, clinicians encountering unilateral presentation should still consider drug-induced etiology 7.
Clinical Implications
When evaluating a man on spironolactone (25-100 mg daily for 2-5 years) with gynecomastia:
- Expect bilateral involvement in most cases
- Do not dismiss spironolactone as the cause if presentation is unilateral
- The pain and swelling typically resolve within weeks to months after discontinuation 7
- Consider switching to eplerenone (a more selective MRA) or amiloride as alternatives 2
- In younger males, dose reduction to ≤50 mg daily may resolve the gynecomastia if it has not progressed to advanced size 2
Common pitfall: Assuming unilateral gynecomastia cannot be drug-induced and pursuing unnecessary workup for other etiologies (such as breast cancer) without first attempting drug discontinuation or substitution.